

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116 - EXPEDITED PROCEDURE

Page 2
Dkt: 109.034US1

Serial Number: 09/096,749

Filing Date: June 12, 1998

Title: ARTIFICIAL ANTIBODY POLYPEPTIDES

[wherein the β -strand domain of the monobody has at least a 50% total amino acid sequence homology to the corresponding amino acid sequence of wild-type Fn3's β -strand domain sequence]

wherein the polypeptide monobody binds to a specific binding partner (SBP) to form a polypeptide:SBP complex.

2. [Twice Amended] The monobody of claim 1, wherein [the] at least one loop region binds to a specific binding partner (SBP) to form a polypeptide:SBP complex having a dissociation constant of less than 10^{-6} moles/liter.
4. [Twice Amended] The monobody of claim 1, wherein [the] a loop region comprises amino acid residues:
 - i) from 15 to 16 inclusive in an AB loop;
 - ii) from 22 to 30 inclusive in a BC loop;
 - iii) from 39 to 45 inclusive in a CD loop;
 - iv) from 51 to 55 inclusive in a DE loop;
 - v) from 60 to 66 inclusive in an EF loop; or
 - vi) from 76 to 87 inclusive in an FG loop.
5. [Twice Amended] The monobody of claim 1, wherein the monobody loop region sequence varies from the wild-type Fn3 loop region sequence by the deletion or replacement of [2 to 25] at least two amino acids in the loop region.
6. [Unchanged] The monobody of claim 1, wherein the monobody loop region sequence varies from the wild-type Fn3 loop region sequence by the insertion of from 3 to 25 amino acids.